FAST NEWS: Simcere’s profit plunges on investment losses
The Latest: Simcere Pharmaceutical Group Ltd. (2096.HK) on Tuesday forecast its net profit for the first half of this year will be between 427 million yuan ($48.9 million) and 487 million yuan,…
Clinical trials come up short again for Alphamab Oncology
The Chinese pharmaceutical firm has suffered its second clinical setback in a matter of weeks, after its U.S. partner halted trials of a sarcoma drug Key Takeaways: Alphamab Oncology could…
Profit setback for Simcere Pharma in novel drugs quest
The pharmaceutical company’s profits have been buffeted by erratic returns on an equity stake in a fellow developer of innovative drugs Key Takeaways: Simcere Pharmaceutical holds a 9% stake in…
FAST NEWS: Simcere’s revenue jumps on rising innovative drug sales
The latest: Simcere Pharmaceutical Group Ltd. (2096.HK) said on Thursday it expects to report its revenue grew between 24% and 26.3% to between 3.35 billion yuan ($468 million) and 3.41 billion yuan in…
3D Medicines Bleeds Red Ink As It Struggles to Swim in ‘Red Ocean’
The loss-making innovative oncology drug company with just one approved product on the market is making a third tilt for a listing on the Hong Kong Stock Exchange Key Takeaways:…
Recent Articles
RELATED ARTICLES
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK -
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
-
No respite for RemeGen as problems and losses pile up
9995.HK 688331.SHG
-
BeiGene heads for profit milestone after hemorrhaging cash
6160.HK ONC.US 688235.SHG
- Cancer drug maker Genfleet joins Hong Kong IPO influx
- Innogen Pharma jostles for a slice of the weight-loss market
